ACRS vs. BFLY

In the year-to-date period, ACRS achieves a -49.60% return, which is significantly lower than BFLY's -24.68% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Aclaris Therapeutics, Inc. (ACRS) and Butterfly Network, Inc. (BFLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current ACRS Sharpe Ratio is 0.07, which is lower than the BFLY Sharpe Ratio of 1.35. The chart below compares the historical Sharpe Ratios of ACRS and BFLY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither ACRS nor BFLY has paid dividends to shareholders.

The maximum ACRS drawdown since its inception was -98.05%, roughly equal to the maximum BFLY drawdown of -97.40%. Use the drawdown chart below to compare losses from any high point for ACRS and BFLY. For additional features, visit the drawdowns tool.

Aclaris Therapeutics, Inc. (ACRS) has a higher volatility of 21.17% compared to Butterfly Network, Inc. (BFLY) at 15.26%. This indicates that ACRS's price experiences larger fluctuations and is considered to be riskier than BFLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Aclaris Therapeutics, Inc. and Butterfly Network, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.